BACKGROUND: Most patients with polymyalgia rheumatica or giant cell arteritis are treated
with glucocorticoid therapy in primary care. We estimated dose–response risks of infection …

The objective of this study was to evaluate glucocorticoid (GC) use in patients with
polymyalgia rheumatica (PMR), giant cell arteritis (GCA) or both diseases (PMR+ GCA) …

Introduction Treatment of giant cell arteritis (GCA) involves immediate initiation of high-dose
glucocorticoid therapy with slow tapering of the dose over many months. Chronic exposure …

Background Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are almost always
treated with glucocorticoids (GCs), but long-term GC use is associated with diabetes mellitus …

Background Glucocorticoids are associated with increased fracture risk and are the
mainstay of treatment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) …

Objective To investigate the use of glucocorticoids (GC s) and related adverse events (AE s)
in a long‐term, geographically defined cohort of patients with polymyalgia rheumatica …

Objective To examine the effect of glucocorticoid use on the risk of various cardiovascular
diseases in patients with polymyalgia rheumatica (PMR). Methods We assembled a …

Objective Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large
and medium-sized arteries. High-dose oral glucocorticoids (GCs) are the mainstay of GCA …

Objective To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell
arteritis (GCA). Methods Using a population based inception cohort, GC therapy details were …

Introduction Oral glucocorticoids (GC) have been the mainstay of treatment for giant cell
arteritis (GCA). We estimated the risk and dose–effect relationship of potential GC-related …